23
ALL23
Reata PharmaceuticalsYear
23
ALL5
20235
20224
20219
2020DEALS // DEV.
23
ALL3
Deals20
DevelopmentsCountry
23
ALL23
U.S.A23
ALL2
Biogen1
Blackstone Life Sciences20
InapplicableTherapeutic Area
23
ALL1
Cardiology/Vascular Diseases20
Genetic Disease1
Infections and Infectious Diseases1
NephrologyStudy Phase
23
ALL15
Approved FDF7
Phase III1
PreclinicalDeal Type
23
ALL2
Acquisition1
Financing20
InapplicableProduct Type
23
ALL23
Other Small MoleculeDosage Form
23
ALL23
Oral CapsuleLead Product
23
ALL8
Bardoxolone Methyl15
OmaveloxoloneTarget
23
ALL23
Nrf2Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Biogen
Deal Size : $7,300.0 million
Deal Type : Acquisition
Biogen Completes Acquisition of Reata Pharmaceuticals
Details : Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : $7,300.0 million
September 26, 2023
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Biogen
Deal Size : $7,300.0 million
Deal Type : Acquisition
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Biogen
Deal Size : $7,300.0 million
Deal Type : Acquisition
Biogen to Acquire Reata Pharmaceuticals
Details : Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : $7,300.0 million
July 28, 2023
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Biogen
Deal Size : $7,300.0 million
Deal Type : Acquisition
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Skyclarys™ (omaveloxolone) have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways and indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Skyclarys™ (omaveloxolone) have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways and indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2023
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Skyclarys™ (omaveloxolone) have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress.
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2023
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omaveloxolone is an investigational, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inf...
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RTA 408 (omaveloxolone) is investigational, oral, once-daily activator of Nrf2, transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, inhibiting pro-in...
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2022
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RTA 408 (Omaveloxolone) is investigational, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, inhibiting pro-...
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bardoxolone Methyl
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bardoxolone is orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signa...
Product Name : RTA 402
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2022
Lead Product(s) : Bardoxolone Methyl
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omaveloxolone is an investigational, oral, once-daily, activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, & inhibiting pro-...
Product Name : RTA 408
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2022
Lead Product(s) : Omaveloxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable